glp-1 shortage news today 2025 glp 1 ending New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended GLP-1R Race in 2025: 8

GLP-1 agonists vs Gastric Bypass Cost-Effectiveness GLP-1 agonists are not cost-effective compared to gastric bypass for patients with severe obesity if current drug pricing persists, with an incremental cost-effectiveness ratio exceeding $500,000 per QALY over 10 years

Likewise, in children, allulose was found to be safe

At WellLife Medical Centers, we specialize in personalized treatments to help you achieve optimal health and sustainable weight loss

Kristina Penniston, commented that these patients could potentially serve as a control group when analyzing how obesity affects stone risk

Also, it blocks the growth-inhibiting action of 4hydroxynonenal